COMPANY

Myrtelle

HQ: New York, NY source · myrtellegtx.com ↗ · Mid-Atlantic

Keywords: Canavan disease gene therapy neurology hypomyelinating leukodystrophy 6 hearing

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Apr 1, 2021 Trial start Phase 1/Phase 2: rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT04833907	rAAV-Olig001-ASPA Gene Therapy for Treatment of Children With Typical Canavan Disease	Phase 1/Phase 2	Enrolling by invitation	Apr 1, 2021	Aug 31, 2026 (estimated)